Jan Harrer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jan Harrer has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Jan Dominik
Department of Cardiac Surgery, Charles University in Prague, Faculty of Medicine and Faculty Hospital Hradec Kralove, Hradec Kralove, Czech Republic
17 shared publications - Jan Vojacek
Department of Cardiac Surgery, Charles University, Faculty of Medicine, University Hospital in Hradec Kralove , Hradec Kralove, Czech Republic
17 shared publications - Pavel Zacek
Department of Cardiac Surgery
6 shared publications - Jiri Mandak
Department of Cardiac Surgery, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
5 shared publications - Josef Stasek
Charles University Prague, Faculty of Medicine in Hradec Kralove, 1st Department of Medicine, Hradec Kralove, Czech Republic
4 shared publications - Marek Pojar
Department of Cardiac Surgery, Charles University in Prague, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
4 shared publications
Latest Publications
- 1 August 2017
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 59 (4) , e312-e316
The current technical options for minimally invasive surgical treatment of atrial fibrillation
Minimálně invazivní chirurgická léčba fi brilace síní (FS), stejně jako technické nástroje a chirurgické postupy se stále vyvíjejí. Nejvhodnějšími pacienty pro tuto metodu jsou pacienti s perzistující a dlouhodobě perzistující fi brilací síní. Tento článek popisuje metody a nástroje pro minimálně invazivní chirurgickou léčbu fi brilace síní, které jsou v současnosti k dispozici na českém trhu.
- 1 August 2017
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 59 (4) , e312-e316
The current technical options for minimally invasive surgical treatment of atrial fibrillation
Minimálně invazivní chirurgická léčba fi brilace síní (FS), stejně jako technické nástroje a chirurgické postupy se stále vyvíjejí. Nejvhodnějšími pacienty pro tuto metodu jsou pacienti s perzistující a dlouhodobě perzistující fi brilací síní. Tento článek popisuje metody a nástroje pro minimálně invazivní chirurgickou léčbu fi brilace síní, které jsou v současnosti k dispozici na českém trhu.
- 1 January 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 103 (1) , 83-90
An Expansible Aortic Ring in Aortic Root Remodeling: Exact Position, Pulsatility, Effectiveness, and Stability in Three-Dimensional CT Study
- 1 January 2017
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 103 (1) , 83-90
An Expansible Aortic Ring in Aortic Root Remodeling: Exact Position, Pulsatility, Effectiveness, and Stability in Three-Dimensional CT Study
- Open Access
- 2 April 2016
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-8
Quality of life after aortic valve repair is similar to Ross patients and superior to mechanical valve replacement: a cross-sectional study
In patients after aortic valve surgery, the quality of life is hypothesized to be influenced by the type of the valve procedure. A cross-sectional study on the postoperative quality of life was carried out in patients after aortic valve-sparing surgery (with regards to the age of the patient), Ross procedure and mechanical aortic valve replacement. Quality of life was studied in 139 patients after aortic valve surgery divided into four study groups (Y – aortic valve-sparing procedure at the age below 50 years, mean age 36.2 years; O – aortic valve-sparing procedure at the age 50 years and over, mean age 59.2 years; R – Ross procedure, mean age 37.8 years and M – mechanical aortic valve replacement at the age below 50 years, mean age 39.2 years). SF-36 Short Form and valve-specific questionnaires were mailed to the patients after 6 months or later following surgery (median 26.9 months). In SF-36, the younger aortic valve repair patients and the Ross patients scored significantly better in 4 of 4 physical subscales and in 2 of 4 mental subscales than the older aortic valve repair and mechanical valve replacement patients. In the valve-specific questionnaire; however, all 3 groups free of anticoagulation (Y, O, and R) displayed greater freedom from negative valve-related concerns. Postoperative quality of life is influenced by the type of aortic valve procedure and is negatively linked with mechanical prosthesis implantation and long-term anticoagulation. Aortic valve-sparing strategy should be considered in cases with suitable valve morphology due to favorable clinical results and beneficial impact on the long-term quality of life.
- 2 April 2016
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 16 (1) , 1-8
Open AccessQuality of life after aortic valve repair is similar to Ross patients and superior to mechanical valve replacement: a cross-sectional study
In patients after aortic valve surgery, the quality of life is hypothesized to be influenced by the type of the valve procedure. A cross-sectional study on the postoperative quality of life was carried out in patients after aortic valve-sparing surgery (with regards to the age of the patient), Ross procedure and mechanical aortic valve replacement. Quality of life was studied in 139 patients after aortic valve surgery divided into four study groups (Y – aortic valve-sparing procedure at the age below 50 years, mean age 36.2 years; O – aortic valve-sparing procedure at the age 50 years and over, mean age 59.2 years; R – Ross procedure, mean age 37.8 years and M – mechanical aortic valve replacement at the age below 50 years, mean age 39.2 years). SF-36 Short Form and valve-specific questionnaires were mailed to the patients after 6 months or later following surgery (median 26.9 months). In SF-36, the younger aortic valve repair patients and the Ross patients scored significantly better in 4 of 4 physical subscales and in 2 of 4 mental subscales than the older aortic valve repair and mechanical valve replacement patients. In the valve-specific questionnaire; however, all 3 groups free of anticoagulation (Y, O, and R) displayed greater freedom from negative valve-related concerns. Postoperative quality of life is influenced by the type of aortic valve procedure and is negatively linked with mechanical prosthesis implantation and long-term anticoagulation. Aortic valve-sparing strategy should be considered in cases with suitable valve morphology due to favorable clinical results and beneficial impact on the long-term quality of life.
- 1 April 2015
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 57 (2) , e149-e155
A history of the surgical treatment of aortic regurgitation
Aortic valve sparing strategies have a valuable potential to treat the patient's valvular disease. In contrast to the mitral and tricuspid valve, aortic repair is more difficult with respect to specific valve features. Authors give a historical overview of the evolution of surgical concepts to achieve the valve competency. Over the period of 70 years, manifold innovative approaches were tested in relation to contemporary level of knowledge in search of effective, standardized, safe and durable reconstructive procedures. Current focus on three geometrical components of aortic valve competency is a logical heir to this long-lasting effort
- 1 April 2015
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 57 (2) , e149-e155
A history of the surgical treatment of aortic regurgitation
Aortic valve sparing strategies have a valuable potential to treat the patient's valvular disease. In contrast to the mitral and tricuspid valve, aortic repair is more difficult with respect to specific valve features. Authors give a historical overview of the evolution of surgical concepts to achieve the valve competency. Over the period of 70 years, manifold innovative approaches were tested in relation to contemporary level of knowledge in search of effective, standardized, safe and durable reconstructive procedures. Current focus on three geometrical components of aortic valve competency is a logical heir to this long-lasting effort
- 25 July 2014
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 29 (5) , 757-762
Thoracoscopic Radiofrequency Ablation for Lone Atrial Fibrillation: Box-Lesion Technique
We report the feasibility and outcomes of box-lesion ablation technique to treat stand-alone atrial fibrillation (AF). There were 41 patients with a mean age of 57.6 ± 8.0 years who underwent bilateral totally thoracoscopic ablation of symptomatic paroxysmal AF (n = 24; 58.5%), persistent AF (n = 9; 22.0%), or long-standing persistent AF (n = 8; 19.5%). The box-lesion procedure included bilateral pulmonary vein and left atrial posterior wall ablation using irrigated bipolar radiofrequency with documentation of conduction block. There were no intra- or perioperative ablation-related complications. There was no operative mortality, no myocardial infarction, and no stroke. Skin-to-skin procedure time was 119.5 ± 23.7 minutes and the postoperative average length of stay was 7.4 ± 2.5 days. At discharge, 38 patients (93%) were in sinus rhythm. Median follow-up time was 641 days (ranges, 185-1636 days). At six months postsurgery, 31 patients of 41 (76%) were free from AF without the need of antiarrhythmic drugs. One-year success rate was 73% (off antiarrhythmic drugs). Eight patients (19.5%) underwent catheter reablation. Thirty-six patients (90%) were in sinus rhythm at six months after the last performed ablation (surgical ablation or catheter reablation). At 12 months follow-up, 61% patients discontinued oral anticoagulant therapy. The thoracoscopic box-lesion ablation procedure is a safe, effective, and minimally invasive method for the treatment of isolated (lone) AF. This procedure provided excellent short-term freedom from AF.
- 25 July 2014
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 29 (5) , 757-762
Thoracoscopic Radiofrequency Ablation for Lone Atrial Fibrillation: Box-Lesion Technique
We report the feasibility and outcomes of box-lesion ablation technique to treat stand-alone atrial fibrillation (AF). There were 41 patients with a mean age of 57.6 ± 8.0 years who underwent bilateral totally thoracoscopic ablation of symptomatic paroxysmal AF (n = 24; 58.5%), persistent AF (n = 9; 22.0%), or long-standing persistent AF (n = 8; 19.5%). The box-lesion procedure included bilateral pulmonary vein and left atrial posterior wall ablation using irrigated bipolar radiofrequency with documentation of conduction block. There were no intra- or perioperative ablation-related complications. There was no operative mortality, no myocardial infarction, and no stroke. Skin-to-skin procedure time was 119.5 ± 23.7 minutes and the postoperative average length of stay was 7.4 ± 2.5 days. At discharge, 38 patients (93%) were in sinus rhythm. Median follow-up time was 641 days (ranges, 185-1636 days). At six months postsurgery, 31 patients of 41 (76%) were free from AF without the need of antiarrhythmic drugs. One-year success rate was 73% (off antiarrhythmic drugs). Eight patients (19.5%) underwent catheter reablation. Thirty-six patients (90%) were in sinus rhythm at six months after the last performed ablation (surgical ablation or catheter reablation). At 12 months follow-up, 61% patients discontinued oral anticoagulant therapy. The thoracoscopic box-lesion ablation procedure is a safe, effective, and minimally invasive method for the treatment of isolated (lone) AF. This procedure provided excellent short-term freedom from AF.
- 12 June 2014
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 29 (5) , 585-592
Valve Cuspidity: A Risk Factor for Aortic Valve Repair?
The aim of this study was to analyze short- and mid-term results after aortic valve (AV) repair with particular regard to the impact of valve cuspidity (bicuspid versus tricuspid aortic valve). One hundred patients with aortic regurgitation (AR) undergoing aortic valve repair between November 2007 and October 2012 were included in the study. Sixty patients had bicuspid AV (BAV group; 11 females) and 40 patients had tricuspid AV (TAV group; 13 females). AR > grade 2 was present in 47 (78%) patients in the BAV and in 35 (88%) patients in the TAV group. Follow-up was complete in 100% and median was 25 months. Isolated aortic valve repair was performed in 27 (45%) of BAV patients and in six (15%) of TAV patients. Replacement of the ascending aorta and/or aortic root was performed in 33 (55%) of BAV patients and in 34 (86%) of TAV patients. There was no death within 30 days postoperatively, while two patients died (TAV group) during the follow-up period. There was no statistical difference between BAV and TAV groups with regard to the survival (100 ± 0% vs. 95 ± 4%, p = 0.102), the three-year freedom from AV-related reoperation (90 ± 5% vs. 89 ± 6%, p = 0.456), and the three-year freedom from AR grade > 2 (86 ± 6% vs. 82 ± 7%, p = 0.866), respectively. This study demonstrates no difference in mid-term results after regurgitant bicuspid and tricuspid aortic valve repair, suggesting that bicuspid valve may not be a risk factor for aortic valve repair.
- 12 June 2014
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 29 (5) , 585-592
Valve Cuspidity: A Risk Factor for Aortic Valve Repair?
The aim of this study was to analyze short- and mid-term results after aortic valve (AV) repair with particular regard to the impact of valve cuspidity (bicuspid versus tricuspid aortic valve). One hundred patients with aortic regurgitation (AR) undergoing aortic valve repair between November 2007 and October 2012 were included in the study. Sixty patients had bicuspid AV (BAV group; 11 females) and 40 patients had tricuspid AV (TAV group; 13 females). AR > grade 2 was present in 47 (78%) patients in the BAV and in 35 (88%) patients in the TAV group. Follow-up was complete in 100% and median was 25 months. Isolated aortic valve repair was performed in 27 (45%) of BAV patients and in six (15%) of TAV patients. Replacement of the ascending aorta and/or aortic root was performed in 33 (55%) of BAV patients and in 34 (86%) of TAV patients. There was no death within 30 days postoperatively, while two patients died (TAV group) during the follow-up period. There was no statistical difference between BAV and TAV groups with regard to the survival (100 ± 0% vs. 95 ± 4%, p = 0.102), the three-year freedom from AV-related reoperation (90 ± 5% vs. 89 ± 6%, p = 0.456), and the three-year freedom from AR grade > 2 (86 ± 6% vs. 82 ± 7%, p = 0.866), respectively. This study demonstrates no difference in mid-term results after regurgitant bicuspid and tricuspid aortic valve repair, suggesting that bicuspid valve may not be a risk factor for aortic valve repair.
- 1 April 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 97 (4) , e119
Penetrating Aortic Injury
- 1 April 2014
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 97 (4) , e119
Penetrating Aortic Injury
- 1 December 2013
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 55 (6) , e479-e486
Aortic valve repair in patients with aortic regurgitation: Experience with the first 100 cases
IntroductionThe aim of this study was to analyze short- and mid-term results of aortic valve repair.Material and methodsOne hundred consecutive patients (24 females; mean age 50.3 years, range 23–77 years) with aortic regurgitation underwent aortic valve repair between November 2007 and October 2012. Sixty patients had bicuspid aortic valve, and 82 patients demonstrated aortic regurgitation greater than mild (> grade 2). The ascending aorta/aortic root was replaced in 67 patients. Aortic cusp repair was necessary in 74 patients and additional aortic annulus stabilization was required in 48 cases. Follow-up ranged from 1 to 59 months (cumulative of 220 patient-years, median 25 months) and was complete in 100%.ResultsThere was no 30-day mortality and two patients died in the follow-up. The overall 4-year survival was 98% and freedom from cardiac death was 99% at 4 years. During the follow-up eight patients underwent aortic valve-related reoperation due to progression of aortic regurgitation and another six patients showed aortic regurgitation more than mild (> grade 2). In both aspects there was no statistically significant difference between patients without and with aortic root replacement (p=0.402 and p=0.650). There were no significant bleeding or thromboembolic events during the follow-up.ConclusionsShort- and mid-term data analysis revealed an excellent survival and acceptable results of aortic repair, comparable with other larger published studies. We think, therefore, aortic valve repair should be a part of contemporary cardio-surgical armamentarium, especially in younger patients with an appropriate indication
- 1 December 2013
- Published by Czech Society of Cardiology in Cor et Vasa
- Vol. 55 (6) , e479-e486
Aortic valve repair in patients with aortic regurgitation: Experience with the first 100 cases
IntroductionThe aim of this study was to analyze short- and mid-term results of aortic valve repair.Material and methodsOne hundred consecutive patients (24 females; mean age 50.3 years, range 23–77 years) with aortic regurgitation underwent aortic valve repair between November 2007 and October 2012. Sixty patients had bicuspid aortic valve, and 82 patients demonstrated aortic regurgitation greater than mild (> grade 2). The ascending aorta/aortic root was replaced in 67 patients. Aortic cusp repair was necessary in 74 patients and additional aortic annulus stabilization was required in 48 cases. Follow-up ranged from 1 to 59 months (cumulative of 220 patient-years, median 25 months) and was complete in 100%.ResultsThere was no 30-day mortality and two patients died in the follow-up. The overall 4-year survival was 98% and freedom from cardiac death was 99% at 4 years. During the follow-up eight patients underwent aortic valve-related reoperation due to progression of aortic regurgitation and another six patients showed aortic regurgitation more than mild (> grade 2). In both aspects there was no statistically significant difference between patients without and with aortic root replacement (p=0.402 and p=0.650). There were no significant bleeding or thromboembolic events during the follow-up.ConclusionsShort- and mid-term data analysis revealed an excellent survival and acceptable results of aortic repair, comparable with other larger published studies. We think, therefore, aortic valve repair should be a part of contemporary cardio-surgical armamentarium, especially in younger patients with an appropriate indication
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Serum 100B protein in detection of brain injury in patients undergoing transcatheter aortic valve implantation
- 1 August 2013
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (suppl 1)
Serum 100B protein in detection of brain injury in patients undergoing transcatheter aortic valve implantation
- 1 August 2013
- Published by IMR Press in The Heart Surgery Forum
- Vol. 16 (4) , 205-7
Recombinant Activated Factor VII Administration after Pulmonary Embolectomy: Case Report
Bleeding management in cardiac surgery could be a great challenge for the surgeon and a life-threatening moment for the patient. Despite the fact that recombinant activated factor VII is now widely accepted as a useful adjunct in the management of postcardiotomy coagulopathy, its use in the course of recent thromboembolic event is rarely described. We hereby present a case of rescue recombinant activated factor VII administration to manage a severe coagulation disorder during surgical pulmonary embolectomy performed under cardiopulmonary bypass.
- 1 August 2013
- Published by IMR Press in The Heart Surgery Forum
- Vol. 16 (4) , 205-7
Recombinant Activated Factor VII Administration after Pulmonary Embolectomy: Case Report
Bleeding management in cardiac surgery could be a great challenge for the surgeon and a life-threatening moment for the patient. Despite the fact that recombinant activated factor VII is now widely accepted as a useful adjunct in the management of postcardiotomy coagulopathy, its use in the course of recent thromboembolic event is rarely described. We hereby present a case of rescue recombinant activated factor VII administration to manage a severe coagulation disorder during surgical pulmonary embolectomy performed under cardiopulmonary bypass.